Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 13/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601287 | 0.74 | GLA (0.45) | MTORMAP3K12TNFPIK3CA | |
| SCHEMBL21031807 | 0.74 | GLA (0.45) | MTORMAP3K12TNFPIK3CA | |
| SCHEMBL3275270 | 0.74 | PARP1 (0.37) | PARP1 | |
| SCHEMBL29208696 | 0.74 | KDR (0.39) | PIK3CA | |
| SCHEMBL29634226 | 0.72 | PARP1 (0.36) | PARP1 | |
| SCHEMBL22802074 | 0.72 | PARP1 (0.36) | PARP1 | |
| SCHEMBL18072106 | 0.72 | MTOR (0.40) | MTORMAP3K12TNFPIK3CA | |
| SCHEMBL3643010 | 0.72 | ALDH1A1 (0.43) | MTORMAP3K12TNFPIK3CA | |
| SCHEMBL22583377 | 0.71 | DDR1 (0.40) | MTORMAP3K12PIK3CA | |
| SCHEMBL182671 | 0.71 | HTT (0.54) | MTORMAP3K12TNFPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217095-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SYNRX THERAPEUTICS (HANGZHOU) CO., LTD. (CN) | 2023-11-16 | — | — | WO | disclosed |
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | MTOR 4568/4885MAP3K12 3203/4885TNF 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.